Our results showed that c-Met overexpression was independent of hormone receptor status and there was no statistical significance of c-Met overexpression between TNBC and non-TNBC group, which indicated that c-Met could be a target for breast cancer regardless of hormone status. This evidence concerns the gene MET and breast carcinoma.